EMBRACE Study: Enduring Migraine Benefit From Responsive Artery Coil Embolization

Starting soon · Not applicable

Conditions studied: Migraine Disorders, Refractory Migraine, Chronic Migraine

In brief

This single-site, open-label pilot study evaluates the safety, feasibility, and potential durability of the TEMMA procedure (Targeted Embolization for Migraine Management), an endovascular treatment strategy targeting meningeal arterial contributors to migraine. Adults aged 18-60 with refractory migraine despite prior preventive therapies are eligible. The study assesses migraine outcomes over 12 months using patient-reported headache frequency, pain intensity, acute medication use, migraine-related disability (MIDAS), and quality-of-life measures (MSQ v2.1).

Key facts

Study ID

NCT07313800

Run by

Cortex Neurovascular

People needed

25

Starts

2026-03-01

Expected to finish

2028-03-01

Last updated by the study team

2026-02-04

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18-60 years
• Diagnosis of migraine (with or without aura)
• ≥8 headache days per month
• Failure of ≥2 preventive medication classes
• Ability to complete electronic headache diary and surveys
• Ability to provide informed consent

You may not qualify if…

• Secondary headache disorders
• Prior MMA embolization
• Contraindication to angiography or embolization
• Pregnancy
• Inability to comply with follow-up

Where it is running

• Cortex Neurovascular / TRA Union — Tacoma, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.